Does the media favor EWTX or PCRX?

In the previous week, Pacira BioSciences had 7 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 25 mentions for Pacira BioSciences and 18 mentions for Edgewise Therapeutics. Pacira BioSciences' average media sentiment score of 0.70 beat Edgewise Therapeutics' score of -0.24 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pacira BioSciences 6 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PCRX or CPRX?

In the previous week, Pacira BioSciences had 24 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 25 mentions for Pacira BioSciences and 1 mentions for Catalyst Pharmaceuticals. Pacira BioSciences' average media sentiment score of 0.70 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 6 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Catalyst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer OGN or PCRX?

In the previous week, Pacira BioSciences had 22 more articles in the media than Organon & Co.. MarketBeat recorded 25 mentions for Pacira BioSciences and 3 mentions for Organon & Co.. Pacira BioSciences' average media sentiment score of 0.70 beat Organon & Co.'s score of 0.68 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 6 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PCRX or GPCR?

In the previous week, Pacira BioSciences had 13 more articles in the media than Structure Therapeutics. MarketBeat recorded 25 mentions for Pacira BioSciences and 12 mentions for Structure Therapeutics. Pacira BioSciences' average media sentiment score of 0.70 beat Structure Therapeutics' score of -0.27 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 6 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ARQT or PCRX?

In the previous week, Arcutis Biotherapeutics had 13 more articles in the media than Pacira BioSciences. MarketBeat recorded 38 mentions for Arcutis Biotherapeutics and 25 mentions for Pacira BioSciences. Arcutis Biotherapeutics' average media sentiment score of 0.73 beat Pacira BioSciences' score of 0.70 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 8 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Pacira BioSciences 6 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pacira BioSciences (PCRX) Competitors

$24.43 -0.59 (-2.36%)

As of 04:00 PM Eastern

Compare

PCRX vs. EWTX, CPRX, OGN, GPCR, and ARQT

Should you buy Pacira BioSciences stock or one of its competitors? Pacira BioSciences's main competitors and comparable companies include Edgewise Therapeutics (EWTX), Catalyst Pharmaceuticals (CPRX), Organon & Co. (OGN), Structure Therapeutics (GPCR), and Arcutis Biotherapeutics (ARQT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Pacira BioSciences compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Pacira BioSciences (NASDAQ:PCRX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Pacira BioSciences has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Pacira BioSciences	$726.41M	1.34	$7.03M	$0.35	69.80

Edgewise Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Edgewise Therapeutics currently has a consensus price target of $48.75, indicating a potential upside of 9.35%. Pacira BioSciences has a consensus price target of $29.80, indicating a potential upside of 21.98%. Given Pacira BioSciences' higher possible upside, analysts plainly believe Pacira BioSciences is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Pacira BioSciences had 7 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 25 mentions for Pacira BioSciences and 18 mentions for Edgewise Therapeutics. Pacira BioSciences' average media sentiment score of 0.70 beat Edgewise Therapeutics' score of -0.24 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacira BioSciences	6 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has a net margin of 1.96% compared to Edgewise Therapeutics' net margin of 0.00%. Pacira BioSciences' return on equity of 9.68% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Pacira BioSciences	1.96%	9.68%	5.30%

99.7% of Pacira BioSciences shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Pacira BioSciences beats Edgewise Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Pacira BioSciences compare to Catalyst Pharmaceuticals?

Pacira BioSciences (NASDAQ:PCRX) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Pacira BioSciences presently has a consensus target price of $29.80, suggesting a potential upside of 21.98%. Catalyst Pharmaceuticals has a consensus target price of $32.00, suggesting a potential upside of 1.62%. Given Pacira BioSciences' higher probable upside, equities analysts plainly believe Pacira BioSciences is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Catalyst Pharmaceuticals has lower revenue, but higher earnings than Pacira BioSciences. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.34	$7.03M	$0.35	69.80
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

In the previous week, Pacira BioSciences had 24 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 25 mentions for Pacira BioSciences and 1 mentions for Catalyst Pharmaceuticals. Pacira BioSciences' average media sentiment score of 0.70 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	6 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Catalyst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Pacira BioSciences' net margin of 1.96%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Pacira BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	1.96%	9.68%	5.30%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Pacira BioSciences has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Summary

Catalyst Pharmaceuticals beats Pacira BioSciences on 11 of the 17 factors compared between the two stocks.

How does Pacira BioSciences compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Pacira BioSciences (NASDAQ:PCRX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Organon & Co. has higher revenue and earnings than Pacira BioSciences. Organon & Co. is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.70
Pacira BioSciences	$726.41M	1.34	$7.03M	$0.35	69.80

In the previous week, Pacira BioSciences had 22 more articles in the media than Organon & Co.. MarketBeat recorded 25 mentions for Pacira BioSciences and 3 mentions for Organon & Co.. Pacira BioSciences' average media sentiment score of 0.70 beat Organon & Co.'s score of 0.68 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	6 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has a net margin of 3.41% compared to Pacira BioSciences' net margin of 1.96%. Organon & Co.'s return on equity of 88.97% beat Pacira BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Pacira BioSciences	1.96%	9.68%	5.30%

Organon & Co. currently has a consensus target price of $11.40, suggesting a potential downside of 16.36%. Pacira BioSciences has a consensus target price of $29.80, suggesting a potential upside of 21.98%. Given Pacira BioSciences' stronger consensus rating and higher possible upside, analysts plainly believe Pacira BioSciences is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Organon & Co. has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Summary

Pacira BioSciences beats Organon & Co. on 9 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to Structure Therapeutics?

Pacira BioSciences (NASDAQ:PCRX) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Pacira BioSciences has a net margin of 1.96% compared to Structure Therapeutics' net margin of 0.00%. Pacira BioSciences' return on equity of 9.68% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	1.96%	9.68%	5.30%
Structure Therapeutics	N/A	-26.12%	-24.85%

99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pacira BioSciences has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.43, suggesting that its share price is 243% less volatile than the broader market.

Pacira BioSciences has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.34	$7.03M	$0.35	69.80
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

In the previous week, Pacira BioSciences had 13 more articles in the media than Structure Therapeutics. MarketBeat recorded 25 mentions for Pacira BioSciences and 12 mentions for Structure Therapeutics. Pacira BioSciences' average media sentiment score of 0.70 beat Structure Therapeutics' score of -0.27 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	6 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pacira BioSciences presently has a consensus target price of $29.80, indicating a potential upside of 21.98%. Structure Therapeutics has a consensus target price of $110.91, indicating a potential upside of 106.11%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

Pacira BioSciences beats Structure Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Pacira BioSciences compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Pacira BioSciences (NASDAQ:PCRX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Pacira BioSciences' net margin of 1.96%. Arcutis Biotherapeutics' return on equity of 15.05% beat Pacira BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Pacira BioSciences	1.96%	9.68%	5.30%

99.7% of Pacira BioSciences shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Arcutis Biotherapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Pacira BioSciences has higher revenue and earnings than Arcutis Biotherapeutics. Pacira BioSciences is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.66	-$16.14M	$0.21	123.43
Pacira BioSciences	$726.41M	1.34	$7.03M	$0.35	69.80

In the previous week, Arcutis Biotherapeutics had 13 more articles in the media than Pacira BioSciences. MarketBeat recorded 38 mentions for Arcutis Biotherapeutics and 25 mentions for Pacira BioSciences. Arcutis Biotherapeutics' average media sentiment score of 0.73 beat Pacira BioSciences' score of 0.70 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	8 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Pacira BioSciences	6 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics currently has a consensus price target of $35.57, suggesting a potential upside of 37.24%. Pacira BioSciences has a consensus price target of $29.80, suggesting a potential upside of 21.98%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Arcutis Biotherapeutics beats Pacira BioSciences on 12 of the 16 factors compared between the two stocks.

Get Pacira BioSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCRX vs. The Competition

Export

Metric	Pacira BioSciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$997.34M	$11.95B	$7.06B	$12.95B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	16.04	788.51	269.75	24.74
Price / Sales	1.34	967.70	652.34	108.60
Price / Cash	6.49	15.12	28.89	37.44
Price / Book	1.52	10.33	11.27	6.42
Net Income	$7.03M	$2.77B	$3.45B	$347.12M
7 Day Performance	-9.25%	2.04%	3.56%	2.48%
1 Month Performance	-4.12%	-1.57%	-0.58%	-1.04%
1 Year Performance	-2.98%	191.33%	77.52%	23.22%

Pacira BioSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCRX Pacira BioSciences	3.4113 of 5 stars	$24.43 -2.4%	$29.80 +22.0%	-0.6%	$997.34M	$726.41M	16.04	720	Earnings Report Analyst Upgrade
EWTX Edgewise Therapeutics	1.9618 of 5 stars	$38.38 -0.1%	$48.75 +27.0%	+243.2%	$4.13B	N/A	N/A	60	News Coverage Positive News Earnings Report Analyst Revision
CPRX Catalyst Pharmaceuticals	3.061 of 5 stars	$31.49 flat	$32.00 +1.6%	N/A	$3.86B	$596.96M	18.10	80	Positive News
OGN Organon & Co.	1.6172 of 5 stars	$13.57 +0.1%	$11.40 -16.0%	+47.5%	$3.56B	$6.22B	17.62	10,000
GPCR Structure Therapeutics	1.9244 of 5 stars	$48.36 +0.7%	$110.55 +128.6%	+225.8%	$3.41B	N/A	N/A	136	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCRX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacira BioSciences (PCRX) Competitors

PCRX vs. EWTX, CPRX, OGN, GPCR, and ARQT

How does Pacira BioSciences compare to Edgewise Therapeutics?

Summary

How does Pacira BioSciences compare to Catalyst Pharmaceuticals?

Summary

How does Pacira BioSciences compare to Organon & Co.?

Summary

How does Pacira BioSciences compare to Structure Therapeutics?

Summary

How does Pacira BioSciences compare to Arcutis Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCRX vs. The Competition

Pacira BioSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacira BioSciences (PCRX) Competitors

PCRX vs. EWTX, CPRX, OGN, GPCR, and ARQT

How does Pacira BioSciences compare to Edgewise Therapeutics?

Which has preferable valuation & earnings, EWTX or PCRX?

Which has more volatility & risk, EWTX or PCRX?

Do analysts prefer EWTX or PCRX?

Does the media favor EWTX or PCRX?

Is EWTX or PCRX more profitable?

Do insiders and institutionals hold more shares of EWTX or PCRX?

Summary

How does Pacira BioSciences compare to Catalyst Pharmaceuticals?

Do institutionals and insiders have more ownership in PCRX or CPRX?

Do analysts prefer PCRX or CPRX?

Which has better earnings & valuation, PCRX or CPRX?

Does the media refer more to PCRX or CPRX?

Is PCRX or CPRX more profitable?

Which has more risk & volatility, PCRX or CPRX?

Summary

How does Pacira BioSciences compare to Organon & Co.?

Do insiders & institutionals have more ownership in OGN or PCRX?

Which has stronger valuation & earnings, OGN or PCRX?

Does the media prefer OGN or PCRX?

Is OGN or PCRX more profitable?

Do analysts recommend OGN or PCRX?

Which has more risk & volatility, OGN or PCRX?

Summary

How does Pacira BioSciences compare to Structure Therapeutics?

Is PCRX or GPCR more profitable?

Do insiders & institutionals believe in PCRX or GPCR?

Which has more risk & volatility, PCRX or GPCR?

Which has preferable earnings and valuation, PCRX or GPCR?

Does the media favor PCRX or GPCR?

Do analysts recommend PCRX or GPCR?

Summary

How does Pacira BioSciences compare to Arcutis Biotherapeutics?

Is ARQT or PCRX more profitable?

Do insiders & institutionals hold more shares of ARQT or PCRX?

Which has more volatility & risk, ARQT or PCRX?

Which has preferable valuation & earnings, ARQT or PCRX?

Does the media refer more to ARQT or PCRX?

Do analysts rate ARQT or PCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCRX vs. The Competition

Pacira BioSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools